- Vincent Launay-VacherClinical Pharmacology
France, C-KIN President
Dr Vincent Launay-Vacher is Clinical Pharmacologist in the Department of Nephrology at Pitie-Salpetriere Hospital in Paris, France. Since 1999, he is Director of Service ICAR, a national medical advisory service and clinical research unit on drug management in patients with renal failure (renal tolerance, dosage adjustment, etc.) dedicated to French physicians, with a focus on oncology.
He received his Doctorate of Pharmacy (PharmD) from the Université René Descartes Paris V and graduated with honours in 2000. He specialized in biodynamics and biopharmacy (pharmacokinetics).
Dr Launay-Vacher is the author of a number of publications mainly in indexed international journals (150), on drug pharmacokinetics and renal effects, and prevalence of kidney disease in cancer. His clinical research activities have focused on the study of drugs’ pharmacokinetics and dosage adjustment in patients with renal insufficiency. He coordinated several National studies, among which the “IRMA” studies (1 and 2) (Renal Insufficiency and Anticancer Medications) on the prevalence of renal insufficiency in French cancer patients, dosage adjustment of anticancer drugs, and impact on survival.
These studies included near 5000 patients each and demonstrated the high prevalence of impaired renal function in cancer patients and the consequences on anticancer drugs handling regarding their potential toxicity and their dosages in such patients. The results of “IRMA” have been presented as oral communications at several international conferences in Oncology. Dr Launay-Vacher is member of the French Society of Nephrology, the International Society of Geriatric Oncology (SIOG), the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the French-speaking Association for Supportive Care in Cancer (AFSOS).
He also collaborates on the Task Force on Renal Insufficiency and Safety in the Elderly Cancer Patient of the SIOG, the Task Force in the Elderly of the EORTC (European Organization for Research and Treatment of Cancer), and he is founding member of the Cancer & the Kidney International Network (C-KIN).
- Matti AaproOncology, Switzerland
C-KIN Executive Secretary
Matti Aapro is presently Dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland.
He coordinates the SPCC programme of the European School of Oncology (ESO) and serves the International Society for Geriatric Oncology (SIOG) as Executive Board member. He has been member of the Board of EORTC and ESMO. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC), and is now on its Board of Directors for 2012-2014.
He is Editor-in-Chief of Critical Reviews in Oncology/Hematology, associate editor for the geriatric section of the Oncologist and founding editor of the Journal of Geriatric Oncology (JGO). He is past Associate Editor for Annals of Oncology. He directs the qualityoflife.elsevierresource.com website. He has authored more than 250 publications and his major interests are new drug development, breast cancer, supportive care, and cancer in the elderly. Dr Aapro has received the 2012 ASCO B.J. Kennedy prize.
- Ben SprangersNephrology, Belgium
Dr Ben Sprangers is assistant professor in the department of nephrology at the University Hospitals Leuven, Belgium. He is also principal investigator in the laboratory of experimental transplantation at the university of Leuven.
He received his Doctorate in Biomedical Sciences from the University of Leuven (KU Leuven) regarding the anti-tumor effects of bone marrow transplantation and adoptive cellular therapy in murine models. He received his training in nephrology at the University Hospitals Leuven (Leuven, Belgium) and at Columbia University Medical Center (New York, USA).
He worked a year under the guidance of Professor Jerry Appel at the Columbia Center for Glomerular Diseases focussing on the treatment of glomerular diseases and vasculitis. Later on, he returned to Columbia University Medical Center to join the laboratory of Megan Sykes (Columbia Center of Translational Immunology) studying the immunologic mechanism following combined kidney/bone marrow transplantation.
His main interests are the interaction between malignancies and the kidney, transplant immunology, and glomerular diseases. Dr Ben Sprangers is the author of numerous publications (30+) in indexed international journals on glomerular diseases and transplant immunology. He has co-authored several chapters in textbooks regarding glomerular disease and kidney transplantation. Dr Ben Sprangers is member of the Belgian Society of Nephrology (NBVN), the American Society of Nephrology (ASN), the Transplantation Society and the American Society of Transplantation (AST). He is executive member of the Cancer & the Kidney International Network (C-KIN).
- Gilberto Castro, Jr.Oncology, BrazilGilberto de Castro Jr. received his MD degree from the University of Sao Paulo Medical School, Brazil, in 1995, and completed his training in Internal Medicine and Clinical Oncology in 2000 at Hospital das Clínicas, University of Sao Paulo Medical School, where he also received his PhD degree in 2009.
He is an ex-fellow of the Medical Oncology Clinic at the Institut Jules Bordet, Brussels, Belgium. His current position is Chief at the Unit of Head and Neck and Thoracic Tumors of the Clinical Oncology Service of the Instituto do Cancer do Estado de Sao Paulo, Brazil – the largest cancer center in the South America. His areas of interest are the medical management of head and neck cancer and thoracic malignancies, focusing on the development of molecular targeted therapies, predictive factors of response to chemotherapy, supportive care and quality of life studies.
- Eric CohenNephrology, USA
Eric Cohen is a Nephrologist whose research is in Radiation Biology. His clinical interests extend to the clinical frontier of Oncology and Nephrology, which overlaps precisely with the mission of C-KIN. His book, Cancer and the Kidney, is the text of reference in this field.
He has developed the concept of mitigation of normal tissue radiation injuries, specifically with regard to late lung and kidney injury after hematopoietic stem cell transplantation. He is on the Faculty at the University of Maryland School of Medicine.
- Gilbert DerayNephrology, France
Pr Gilbert Deray is Professor of Nephrology at Université Paris 6 Pierre et Marie Curie in paris and Nephrologist and Head of the Department of Nephrology at Pitié-Salpêtrière University Hospital in Paris, France. Pr Deray graduated as MD at Université Paris 12 and joined the Department of Nephrology at Pitié-Salpêtrière University Hospital after a fellowship in Clinical Pharmacology at Vanderbilt University, Nashville, Tennessee. Pr Deray became Head of the Department in 1998. He also member of the Pharmacovigilance Committee at Agence Nationale de Sécurité des Médicaments (ANSM), the French drugs agency. He is President of the Organisation and Scientific Committee of the Séminaires Universitaires de Néphrologie, a national annual conference that gathers 1’000 nephrologists each year in Paris.
Pr Deray founded Service ICAR in 1999 with Dr Vincent Launay-Vacher, and has developed specific interests and activities in the field of Cancer and the Kidney, especially on the anemia of cancer patients. Pr Deray authored an impressive number of publications; among which 300 in medical journals indexed in Medline. He is co-editor of “Clinical nephrotoxins”, the reference textbook on “Drugs and the Kidney”.
Pr Deray is member of the French Society of Nephrology, the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA), and the American Society of Nephrology (ASN). He is founding member of the Cancer & the Kidney International Network (C-KIN).
- Michael DooleyClinical Pharmacy, Australia
Professor of Clinical Pharmacy
Co-director, Centre for Medicine Use and Safety
Research & Supervision Interests
- Method for dosage prediction in obese patients
- Drug handling and kinetics
- Outcome measures for clinical pharmacy services
- Clinical pharmacy services in disease management
- Drug therapies for malignancy and symptom control
- Medication safety and use in the aged
- Kenar D. JhaveriNephrology, USA
Kenar D. Jhaveri, MD, is an Associate Professor of Medicine in the Division of Kidney Diseases and Hypertension at the Hofstra Northwell School of Medicine in NY. He practices nephrology at North Shore University Hospital in Great Neck, NY. He completed his residency training at Yale University New Haven Hospital in Internal Medicine and then a fellowship in Nephrology at New York Presbyterian Hospital-Weill Cornell campus.
Dr. Jhaveri’s clinical interest is in glomerular diseases and taking care of patients with renal complications following cancer, bone marrow transplantation and chemotherapy. His most recent research focuses on renal effects of targeted therapies used in cancer. He is one of the founding members of ASN’s workgroup on Onconephrology. He is a columnist for the ASN Kidney News for the section called “Detective Nephron”. He has published on onconephrology and also in using social media and other innovative tools (games, concept maps, role playing, creative writing) to make nephrology a fun and exciting field. In addition, he is the editor of the textbook in onconephrology by Springer released in 2015. He continues to have interest in novel ways of sharing information that can make an impact on all fronts—physicians, allied health staff, and the patients. He is a fellow of American Society of Nephrology, American College of Physicians, and National Kidney Foundation. He has a teaching oriented blog called NephronPower. He is also the founding and current editor for the official blog of the American Journal of Kidney Diseases, www.ajkdblog.org.
- Stuart LichtmanOncology, USA
Stuart M. Lichtman, MD, FACP
Attending, Memorial Hospital for Cancer and Allied Diseases
Member, Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
For the last 30 years, I have been actively involved in treating older patients with cancer. As life expectancy has been increasing, the number of older patients with cancer has also been increasing. They have become the majority of the patients that we evaluate and treat, and as such, they need to become the focus of our endeavors.
My study of Geriatric Oncology started with the recognition that older cancer patients are underserved and undertreated. As an attending in the Division of Oncology, North Shore University Hospital (Manhasset, NY) I began my participation in the CALGB as a member of the Pharmacology and Experimental Therapeutics Committee (1990) and subsequently became one of the original members of the CALGB Cancer in the Elderly Committee (1995). I became a member of the International Society of Geriatric Oncology (SIOG) at its inception in 2000 and became increasingly involved by participation in various taskforces (Chemotherapy, as chair, Geriatric Assessment, Renal Dysfunction, Lymphoma).a member of the Board of Directors (Treasurer, 2010 to present), US National Representative and Scientific Chair of the 2011 meeting. My Geriatric Oncology work also included the Scientific Advisory Board of the Geriatric Oncology Consortium, the Elderly Taskforce of the Gynecologic Oncology Group, Cancer and Aging Research Group and the NCCN Guidelines Taskforce for the treatment, Evaluation of Older Women with Breast Cancer and Editorial Board of the Journal of Geriatric Oncology. I have been a member of ASCO since 1988 and have been an active participant by serving on the Clinical Practice Committee, Scientific Program Committee, Geriatric Oncology Special Interest Group, an invited speaker at Educational Sessions, ASCO University and a faculty member of the ASCO/AACR Vail Clinical Trials workshop for five sessions on the topic of special populations. I have been a guest editor for a special edition devoted to Geriatric Oncology for the Journal of Clinical Oncology (2007 and 2014).
In 2004 I became a faculty member of Memorial Sloan-Kettering Cancer Center. MSKCC organized the 65+ Clinical Geriatric Group, part of its Cancer and Aging program, to achieve the goal of optimizing cancer care for the older patient. I chaired the group 2006-2009. The group is composed of experts in geriatrics, finance, nutrition, occupational therapy, music therapy, pharmacy, physical therapy, psychiatry, social work, palliative care, medical and surgical oncology. We meet on a monthly basis to plan, on an ongoing basis, the building of an infrastructure for multidisciplinary geriatric oncology care in the institution. At MSKCC, I am a member of the Gynecologic Oncology Disease Management Team and the Patient Safety Advisory Council.
I have published over 100 articles in peer review journals, contributed to nine book chapters and edited three books and have been an invited speaker and many national and international meetings on Geriatric Oncology. In 2014 I received the BJ Kennedy Award for Scientific Excellence in Geriatric Oncology.Jean-Baptiste ReyClinical Pharmacy, France
Titles and Diplomas
- Lecturer “Clinical Pharmacy”: University of Reims – Champagne-Ardenne
- Hospital Pharmacist, Head of the Pharmacy Department: Institut Jean Godinot – Reims Regional Cancer Treatment Centre
- PhD: Faculty of Pharmacy, University of Reims – Champagne-Ardenne
- Pharm D: Faculty of Pharmaceutical and Biological Sciences, University Paris V
- M Sc Pharm: Faculty of Pharmaceutical and Biological Sciences, University Paris V
- B Sc Pharm: Faculty of Pharmaceutical and Biological Sciences, University Paris V
- 15 publications indexed in the Medline database
- 40 publications not indexed in the Medline database
- 8 chapters of medical books
- Lecturer “Clinical Pharmacy” (90 hours of lectures + 55 hours of tutorials / year)
- Lecturer in several University Diplomas, Inter-University Degrees.
- Supervision of 18 theses (17 Pharm D and 1 PhD)
- Teaching at the Institute of Nursing Training
- Supervision of pharmacy students and pharmacy residents at Institut Jean Godinot
- Since 2004: European Fellowship for Pharmacists (EFP)
- Scientific Committee since 2012
- President from 2008 to 2012
- Since 2009: American Society of Clinical Oncology (ASCO): active member
- 2005-2011: European Society of Clinical Pharmacy (ESCP)
- Publications Committee (2006-2011): “third reviewer”
- Bureau of the Special Interest Group “Cancer Care” (2004-2011)
Florian ScottéOncology, France
- Editor in Chief: Journal de Pharmacie Clinique (John Libbey Eurotext)
- Member of the Editorial Board: Onko+ (Expressions Santé)
Dr Florian Scotté is Medical Oncologist in the Department of Medical Oncology at George Pompidou European Hospital in Paris, France.
Dr Scotté founded and is Head of the Oncology Supportive Care Unit, and responsible for the outpatient clinic. He received his PhD on Medical Ethics at Université René Descartes Paris V.
Actively involved in teaching in several courses, he created the first inter-universities diploma in Supportive Care in Oncology in France. He is coordinator and co-investigator in a number of clinical trials in oncology supportive care, among which the first which demonstrated the interest of frozen protections against nail and skin toxicity of docetaxel.
Dr Scotté holds the positions of Secretary and chairman of the education and training committee of the French-Speaking Association for Supportive Care in Cancer (AFSOS: Association Francophone pour les Soins Oncologiques de Support). He is the founder and director of Transatlantiques en Oncologie, an annual international congress that gathers oncologists from Europe and the US, from both sides of the Atlantic.
Dr Scotté is member of the AFSOS, MASCC, and ASCO and he is founding member of the Cancer & the Kidney International Network (C-KIN).Hans WildiersOncology, Belgium
Hans Wildiers is a medical oncologist dedicated to breast cancer research and cancer in older individuals. He is staff member at the department of medical oncology in the University Hospital Gasthuisberg Leuven, Belgium since 2004. Since 2005 he is full professor at the Catholic University of Leuven (KULeuven), faculty of Medicine, department of Oncology. He has been coordinator of many academic studies in the field of breast cancer and geriatric oncology, and author of more than 120 peer reviewed papers in 11 years.
- European Organisation for Research and treatment of Cancer (EORTC): secretary of the task force cancer in the elderly since 2007 and chairman from 2009 till 2015.
- Belgian Society of Medical Oncology (BSMO); board member since 2007.
- International society of Geriatric Oncology (SIOG): national representative for Belgium since 2005; member of the steering committee of the ‘SIOG national representative group’ since 2008; board member from 2008 till 2012.
- Board member ‘Nederlandse oncologiedagen’ since 2007.
- Board member of the scientific commission of the ‘Stichting Emmanuel van der Schueren’ (Vlaamse Liga tegen kanker) since 2007.
- Board member of the editing committee of the Belgian Journal of Medical Oncology (BJMO) since 2007.
- Board member of the medical council of the University Hospitals Leuven from 2009 till 2011.
- Associate editor of Annals of Oncology as from January 2010.
- Scientific committee for ‘Le Journal d’OncoGériatrie’ since November 2009.
- Member of the scientific committee of the Journal of Geriatric Oncology since 2010.
- Board member of the Geriatric Expert Group (GEG) of the EMA (European Medicine Agency) since 2011.
- 2011: Coordinator of the Belgian Breast Cancer Guidelines Development Group (GDG), under the umbrella of KCE (Belgian Health Care Knowledge Centre).
- Reviewer for many journals: European journal of cancer, Critical reviews in hematology/oncology, Belgisch tijdschrift voor geneeskunde, Annals of Oncology, Drugs in R&D, Drugs and aging, The Oncologist, Journal of palliative care, Belgian Journal of Medical Oncology (BJMO), Lancet Oncology, Journal of Clinical Oncology.
Awards and grants
- 2000: scholarship for scientific research of the Flemish Work against Cancer (stichting Emmanuel van de Schueren).
- 2001-2003: scholarship as ‘aspirant’ of the ‘Nationaal Fonds voor Wetenschappelijk Onderzoek’ (FWO) Belgium.
- 2004: Amgen award 2004 of the Belgian Society of Medical Oncology (BSMO).
- 2004: Pfizer educational grant KU Leuven.
- 2009: LKI Novartis award (Leuven Cancer Institute).
- 2010-2015: Senior Clinical Investigator of the research Foundation – Flanders (Belgium) (FWO).